Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
View/ Open
Volume
21
Pagination
100279 - ?
DOI
10.1016/j.ensci.2020.100279
Journal
eNeurologicalSci
Metadata
Show full item recordAbstract
Objective: To describe a fatal case of influenza A pneumonia in a patient with severe lymphopenia after receiving subcutaneous cladribine to treat her multiple sclerosis (MS). Methods: Case report. Results: A 53-year-old woman developed fatal influenza pneumonia associated with grade 4 lymphopenia two months after receiving a total dose of 60mg subcutaneous cladribine. Despite treatment with oseltamivir, her condition deteriorated and the patient passed away after developing respiratory failure. Conclusion: Cladribine-related lymphopenia is usually mild to moderate, however severe lymphopenia may occur. People with MS, especially those who are immunosuppressed, should be offered the inactivated influenza vaccine annually.
Authors
Mateo-Casas, M; Reyes, S; De Trane, S; Edwards, F; Espasandin, M; Anjorin, G; Baker, D; Schmierer, K; Giovannoni, GCollections
Language
Licence information
Copyright statements
The following license files are associated with this item: